This invention provides a combination of a hypoglycemic, metformin, and an irreversible intestinal gastric and pancreatic lipase inhibitor, Orlistat, for a better control of obesity than with the monotherapy used with each of them this composition provides "low" doses of both drugs to minimize secondary effects and to make use of the synergic effect of both compounds.
